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Background: Using the aggregated data of all sentinel sero-surveys (1991 to 2007), this study aimed to report the
HIV trend among Iranian prisoners.
Method: Overall, we analysed the aggregated data from 397 HIV sero-surveys conducted in 72 prisons (included
155,771 prisoners) from 1991 through 2007.
Results: The overall HIV prevalence was 2.8% (95% CI: 1.8%-4.3%). In 1998, HIV prevalence dramatically increased to
4.5% (95% CI: 1.1%-16.8%), which later became stable at level of 2.8%. Prisons were so heterogeneous regarding HIV
prevalence (0% to 13.2%).
Conclusion: Since the outbreak, the ministry of health has acknowledged prisoners as one of the high-risk groups
for HIV, increased the number of sentinel surveys and on-site harm reduction services to better monitor and response
to the HIV epidemic. The downward trend of HIV prevalence after 2005 suggests the effectiveness of such interventions
which need to be continued.
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Iran, with very strict rules against drug trafficking, has
been used as one of the main transient routes for drugs
and opium trafficking from Afghanistan to other coun-
tries. Consequently, this has made opium and other
drugs easily available for Iranians [1,2]. This put more
people at risk of drug addiction and drug trafficking re-
lated crimes, and so more related incarceration [3,4].
Given the fact that HIV epidemic in Iran is driven by
injecting drug users, prisoners could be at higher risk of
HIV acquisition and further transmission [5-7]. Prisoners
are considered as one of the high-risk groups for HIV in
many countries [6,8]. High prevalence of HIV among
prisoners in compare to general population was reported
in USA (ratio 6:1), France (ratio 10:1) [9].
In Iran, HIV outbreak in prisons was first observed in
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distribution, and reproduction in any mediumgrasped national attention, when the first index HIV cases
were reported in 1995, followed by 58 confirmed cases in
1996. Later, the number of HIV infected prisoners in-
creased to 407 cases in 1997–8. This was reported as the
first HIV outbreak inside prison in Iran [4,10].
Health authorities used the advantage of these out-
breaks to advocate for comprehensive control measures
in- and out-side prisons. Since 2003, the harm reduction
programmes implemented and expanded by increasing
the number of triangular clinics, setting up a free and
voluntary HIV consulting and testing, establishing the
methadone maintenance therapy, spreading the bleach
and disposal razors, distributing free condoms, starting
the needle and syringe exchange programs, educating
prisoners and their families, and running the psycho-
therapy meetings widely, particularly among injecting
drug users, both in- and out-side prisons [11-15].
Meanwhile, to monitor the trend of HIV prevalence
within prisons, HIV sentinel sero-surveys have been im-
plemented widely among prisons, in particular after
1998 outbreak. Such data are available since 1991, buttral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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using the existing HIV sentinel surveillance data, we ex-
plore the HIV trend among prisoners since early 1990s
to monitor the response to prisons’ HIV epidemics in
Iran.Methods
For this analysis, all 397 HIV sentinel sero-surveys were
included which implemented in 72 prisons since 1991.
The venues blood sample was obtained from every re-
cruited prisoner and was tested for anti-HIV antibody
using the enzyme-linked immunosorbent assay (ELISA)
method. It was considered as positive if reconfirmed by
a second ELISA test. The surveys were designed and im-
plemented jointly by Prisons Organization and Center
for Disease Control (CDC). The data of the present
study was collected from 1991 through 2007.
To produce the large database, first the pooled results
of every survey to produce individual records having
HIV status, year and prison name were expanded. Later,
all separated expanded databases were merged into one
database for analysis. The final large database was con-
sisted of 155,771 records as prisoners. Written informed
consent was obtained from the patient for the publica-
tion of this report. The protocols of these surveys and
providing the information of this study have been ap-
proved by the Ministry of Health (MOH), Iran and
ethical committee of Kerman University of Medical
Sciences.
Then, the HIV prevalence was calculated overall and
by year and province. In this analysis, prisons were consid-
ered as the sampling units (clusters). Intra cluster coeffi-
cient (ICC) was reported as a measure for intra-prison
correlation coefficient of HIV. Finally, using GeographicalFigure 1 HIV prevalence among prisoners and number of sentinel seroInformation System (GIS) the HIV spatial distribution in
prisons was illustrated at the level of provinces.
Results
In total, 155,771 prisoners were recruited in the sentinel
surveys, with the average sample size of 392 (range 10 to
2,200). A few surveys were implemented before 1998
HIV outbreak. Since then, the number of surveys has
surged dramatically; so that in recent years more than
50 surveys have been annually carried out in prisons.
Overall HIV prevalence was 2.8% (95% CI: 1.8%-4.3%).
While the HIV was detected at 0% to 0.4% in prisons be-
fore 1998, due to the HIV outbreak in 1998, the HIV
prevalence reached to the maximum of 4.5% (95% CI
1.1%-16.8%). After 1998, HIV prevalence was at 2.8% on
average, ranged from 1.5% to 3.8% (Figure 1).
HIV prevalence varied from 0% to 13.2% in different
prisons. Prisoners located in provinces in west and south
part of Iran had a higher prevalence of HIV (range 3.4% -
13.2%) in comparison with other provinces (Figure 2).
Using Poisson regression model, a significant intra-
prison correlation was observed regarding the HIV
prevalence; (Intra Cluster Coefficient: Overall ICC =0.09;
for surveys between 2000 and 2007: ICC = 0.07; for sur-
vey between 2000 and 2007: ICC = 0.06).
Discussion
The overall HIV prevalence was 2.8%, which is higher
than that of the general population (around 0.1%) [5].
The results demonstrated that the prevalence of HIV in
recent years is more or less constant at the level of 3%, if
not decreasing. However, due to limited surveys con-
ducted prior to 1998, it is difficult to generalize our find-
ing to early 1990s.-surveys implemented in prisons between 1991 and 2007 in Iran.
Figure 2 The spatial distribution of HIV prevalence among prisoners between 1991 and 2007.
Haghdoost et al. Harm Reduction Journal 2013, 10:32 Page 3 of 5
http://www.harmreductionjournal.com/content/10/1/32Farnia et al. in their survey among Iranian prisoners in
2005 estimated the overall HIV prevalence as the level
of 3% (ranged from 0.2% in Khorasan province to 13.5%
in Kermanshah province) [16]. This pattern is very simi-
lar to what was found in our study.
In recent bio-behavioural study of 5530 prisoners from
27 prisons in 2009 in Iran [7], the HIV prevalence was
reported at 2.1% (95% CI: 1.2 - 3.6). This was compar-
able to the findings of the present study. Regarding the
prisoners risk profile, only one-fifth (20.5%) had compre-
hensive knowledge about HIV, and one-fourth (24.7%)
had used condom in their last sexual contact inside
prison. In addition, the overall history of drug injection
was reported by 16.5% of all prisoners and there has
been a strong association between ever drug injection
and being HIV positive (8.1% in ever injected vs. 0.9% in
never injected). In Ohaio prison [17], approximately
12.1% of inmates reported sexual contact during incarcer-
ation, that in around 85% of the time it was with multiple
partners. Only 15.4% used condom during sexual relation-
ship. These behavioural findings indicate that prisoners
are still at risk of HIV acquisition and transmission; there-
fore, it should be monitored by both sentinel sero-surveys
and behavioural surveillance surveys. Specific interven-
tions such as harm reduction for both sexual and injection
related behaviours and providing sufficient and convenient
treatment services are needed to decrease HIV transmis-
sion risk among prisoners [18-22].
Since 1998, any drug user (either injecting or non-
injecting) as far as they only identified as a drug user,
were considered as patient not as a criminal. So, they
were not arrested and be put in jail and prison, but re-
ferred to drug treatment and rehabilitation centers. This
was a remarkable amendment in the anti-narcotic lawand judiciary system. The sharp decrease in HIV preva-
lence inside the prisons in 1999 and 2000 could be partly
explained by reduction in the number of prisoners at
risk for HIV, like injecting drug users, inside the prison
as the effect of the implementation of such policy.
In 2000, first triangular clinic was established inside
Kermanshah prison and later expanded to other prisons
[10]. They provided confidential HIV counseling and
testing services as well as anti-retroviral treatment to eli-
gible HIV positive patients (based on national HIV treat-
ment guideline). Since 2003, harm reduction services/
programs with the focus on needle/syringe exchange pro-
grams and methadone maintenance therapy (expanded to
all 30 provinces included 142 prisons in 2010) became
available to prisoners [13,23]. Such ongoing harm reduc-
tion intervention package for prisoners [15,24,25] can ex-
plain the downward trend of HIV prevalence after 2005
indicates the effectiveness of such interventions and con-
tinuing these programs are needed. This needs further in-
vestigation as the downward trend could be due to higher
mortality.
As prisoners might acquire the HIV infection either
outside or inside the prison, sero-surveys of prisoners at
the point of entry to prison would help to better under-
stand the source of HIV infections among prisoners.
This will also lead health authorities to plan and imple-
ment more effective interventions.
We should acknowledge the limitations of our study.
At the very beginning of the HIV epidemic in prisons,
the identified HIV positive cases have been isolated from
the rest of the prisoners. We do not know the exact
starting date of the isolation strategy and we cannot dis-
tinguish which of the sero-surveys might have been af-
fected by it. The effect of such isolation would be an
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downward trend. Since the isolation strategy was imple-
mented by about 2000 and discontinued, the sharp decrease
between 1998 and 1999–2000 could be partly explained by
it, but it would not affect the observed trend in the recent
decade.
Basically, sentinel surveys only monitor HIV preva-
lence not related behaviours. Therefore, we were not
able to report the HIV epidemics by individual charac-
teristics and behavioural profile. In addition, to get a
more accurate picture for the HIV trend in prisons and
to plan for more effective preventive interventions, re-
peated sero-surveys within every prison is needed. The
focus should be on prisons with either upward trend or
stable but high level of HIV over time.
Conclusion
The overall HIV prevalence among prisoners is 2.8%,
and this rate has been almost constant during recent
years in Iran. Since the outbreak, the ministry of health
has acknowledged prisoners as one of the high-risk
groups for HIV, increased the number of sentinel sur-
veys and on-site harm reduction services to better moni-
tor and response to the HIV epidemic. The downward
trend of HIV prevalence after 2005 indicates the effective-
ness of such interventions which need to be continued.
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